Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison. [PDF]
Adv TherCortesi PA +6 more
europepmc +1 more source
Anti-VEGF therapy for posterior segment disorders: The story so far…. [PDF]
Indian J OphthalmolChawla R.
europepmc +1 more source
Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. [PDF]
CureusBousamri A +6 more
europepmc +1 more source
Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: A case report. [PDF]
J Int Med ResAl Adel F +3 more
europepmc +1 more source
Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]
Front Public HealthHamida JA +7 more
europepmc +1 more source
Exudative retinopathy from retinal vasoproliferative tumor refractory to aflibercept treated with faricimab-svoa. [PDF]
Am J Ophthalmol Case RepKarthik N +4 more
europepmc +1 more source
From bench to bed: The evolution of anti-vascular endothelial growth factor therapies. [PDF]
Indian J OphthalmolSen A, Kohli G, Agarwal A, Chauhan R.
europepmc +1 more source
Anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. [PDF]
Indian J OphthalmolGiridhar A, Lekha T, Chandran K.
europepmc +1 more source
One-Year Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in Japan: A Multicenter Retrospective Study. [PDF]
Clin OphthalmolMizuma R +6 more
europepmc +1 more source
Efficacy and safety of ranibizumab, aflibercept, and conbercept in the treatment of diabetic macular edema: a retrospective comparative study. [PDF]
Sci RepLiu B, Qiao Q, Dang Y.
europepmc +1 more source